echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > CRAL: Comparison of treatment guidelines for pemphigus: systemic glucocorticoids, rituximab and other immunosuppressive therapies

    CRAL: Comparison of treatment guidelines for pemphigus: systemic glucocorticoids, rituximab and other immunosuppressive therapies

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     


    Pemphigus vulgaris (PV) and deciduous pemphigus (PF) are the two main clinical variants


     

    Corticosteroid therapy

    Corticosteroid therapy Corticosteroid therapy






     

    Corticosteroid reduction in maintenance of remission

    Corticosteroid reduction in the maintenance of remission period Corticosteroid reduction in the maintenance of remission period




     

    Relapse/relapse cases

    Relapse/Relapse CaseRelapse/Relapse Case


    Anti-CD20 monoclonal antibody

    Anti-CD20 monoclonal antibodyAnti -CD20 monoclonal antibody


    Rituximab is used as a first-line drug for the treatment of moderate to severe pemphigus


     

    Adjuvant immunosuppressant

    Adjuvant immunosuppressant adjuvant immunosuppressant


     

    Other therapies

    Other therapies Other therapies



    Literature source: Zhao W, Wang J, Zhu H, Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies.
    Clin Rev Allergy Immunol 2021 Aug 04

     

     

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.